Skip to main content

Black Diamond Therapeutics, Inc.

corporate_fare Company Profile

Black Diamond Therapeutics, Inc.

BDTX·NASDAQ·Life Sciences·CIK 0001701541

Black Diamond Therapeutics is a clinical-stage oncology company that develops MasterKey therapies designed to target families of cancer-causing mutations in patients with cancer. The company's approach is based on understanding cancer genetics, onco-protein structure and function, and medicinal chemistry. MasterKey therapies aim to treat a wide range of genetically defined tumors, overcome drug resistance, reduce side effects on healthy cells, and penetrate the brain to treat central nervous system (CNS) diseases. These compounds target families of cancer-causing mutations in established biological pathways. The company's main clinical-stage program is silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor. Silevertinib is currently in a Phase 2 clinical trial for patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The company plans to start a randomized Phase 2 trial of silevertinib in newly diagnosed patients with EGFR altered glioblastoma (GBM) in the second quarter of 2026. Black Diamond Therapeutics aims to provide targeted oncology medicine to patients with genetically defined cancers who have limited treatment options. Their drug development uses findings that mutations throughout a gene can activate cancer and change how drugs interact with their active sites; these mutations can be grouped into families due to similar protein structural changes and shared drug selectivity; and a single molecule can inhibit a family of cancer-causing proteins by targeting the active site. MasterKey therapies were discovered using the proprietary MAP drug discovery engine, which focuses on identifying oncogenic mutations, confirming their cancer-causing nature using cell and tumor models, and pharmacologically inhibiting these mutations while sparing healthy cells.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for BDTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for BDTX spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Black Diamond 10-Q: $102M Cash Into H2 2028, Q3 Net Loss $10.0M
  • Silevertinib Shows 86% CNS Response Rate in Untreated Brain Metastases
  • Black Diamond's Silevertinib Hits 86% CNS-ORR; FDA Backs Path to Registration
  • Black Diamond Sets Nov. 10 Webcast on Silevertinib Phase 2 Data and FDA-Backed Phase 3 Path
  • Black Diamond Therapeutics Reports Positive Phase 2 Silevertinib Results in NSCLC, Plans FDA Meeting

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$70M
Net Income
$22.37M
Diluted EPS
$0.39
Op. Cash Flow
$29.61M
Operating Income
$12.52M
Cash & Equivalents
$20.99M
Debt / Equity
0.00×
Net Margin
32.0%
Shares Outstanding
57.14M sh
Source: 10-K · filed 2026-03-16 · accession 0001701541-26-000009

Short Interest & Short Volume

4.87 days to cover

FINRA reported short interest of 5,106,005 shares in BDTX as of the October 30, 2026 settlement, a 2.1% increase from the prior period — about 4.9 days to cover at its recent average daily volume. On November 20, 2026, 49.2% of BDTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,106,005 shares as of October 30, 2026
Change vs prior period▲ 2.1%
Days to cover4.87 at avg daily volume of 1,049,276
Daily short volume (FINRA facilities)49.2% of 314,571 shares on November 20, 2026
5-day average short volume54.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$1.39 +6.11% today
52-week range · as of 2026-11-10 $1.39 – $4.94
Market cap
$75.28M
Volume
673.4K (0.8× avg)
3-mo avg 841.7K
Live data · 2026-11-22 06:16 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BDTX - Latest Insights

BDTX
Nov 10, 2026, 6:31 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.39 info
Change: -$0.610 (-31%) info
Market Cap: $75.283M info
BDTX
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.00
Real-time Price: $1.39 info
Change: -$0.610 (-31%) info
Market Cap: $75.283M info
BDTX
Nov 10, 2026, 6:28 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.02
Real-time Price: $1.39 info
Change: -$0.630 (-31%) info
Market Cap: $75.283M info
BDTX
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.39 info
Change: -$0.560 (-29%) info
Market Cap: $75.283M info
BDTX
May 21, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.19
Real-time Price: $1.39 info
Change: -$1.80 (-56%) info
Market Cap: $75.283M info
BDTX
May 21, 2026, 5:13 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.27
Real-time Price: $1.39 info
Change: -$1.88 (-57%) info
Market Cap: $75.283M info
BDTX
May 07, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.78
Real-time Price: $1.39 info
Change: -$1.39 (-50%) info
Market Cap: $75.283M info
BDTX
May 07, 2026, 7:20 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.78
Real-time Price: $1.39 info
Change: -$1.39 (-50%) info
Market Cap: $75.283M info
BDTX
Mar 16, 2026, 4:03 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.14
Real-time Price: $1.39 info
Change: -$0.750 (-35%) info
Market Cap: $75.283M info
BDTX
Mar 16, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.14
Real-time Price: $1.39 info
Change: -$0.750 (-35%) info
Market Cap: $75.283M info
BDTX
Mar 16, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.14
Real-time Price: $1.39 info
Change: -$0.750 (-35%) info
Market Cap: $75.283M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets